Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba, 3-2-7 Miya-machi, 310-0105, Mito, Ibaraki, Japan.
Invest New Drugs. 2022 Dec;40(6):1354-1355. doi: 10.1007/s10637-022-01302-x. Epub 2022 Sep 24.
Recently, we read a paper "Dacomitinib overcomes afatinib-refractory carcinomatous meningitis in a lung cancer patient harbouring EGFR Ex.19 deletion and G724S mutation" published in Investigational New Drugs. Their patient had a very rare compound EGFR mutation. To share our experience, we present a case of 58-year-old man with a long-term response to afatinib in a patient with previously unreported compound EGFR mutation. In patients with rare compound EGFR mutations, afatinib might be one of the treatment option.
最近，我们阅读了一篇发表在《Investigational New Drugs》上的论文“Dacomitinib 克服携带 EGFR Ex.19 缺失和 G724S 突变的肺癌患者对 afatinib 耐药的癌性脑膜炎”。他们的患者携带一种非常罕见的复合 EGFR 突变。为了分享我们的经验，我们报告了一例 58 岁男性患者，该患者之前未报道过复合 EGFR 突变，对 afatinib 有长期反应。对于罕见的复合 EGFR 突变患者，afatinib 可能是一种治疗选择。
